Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer

被引：0
|
作者：
Trine Zeeberg Buch-Hansen
Lise Bentzen
Steinbjoern Hansen
Morten Hoeyer
Niels Viggo Jensen
Charlotte Saxe
Lisa Sengeloev
机构：
[1] Herlev University Hospital,Department of Oncology
[2] Aarhus University Hospital,Department of Oncology
[3] Odense University Hospital,Department of Oncology
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 66卷
关键词：
PSA response; Palliation; Chemotherapy; Pain;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：295 / 301
页数：6
相关论文
共 50 条
  • [1] Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer
    Buch-Hansen, Trine Zeeberg
    Bentzen, Lise
    Hansen, Steinbjoern
    Hoeyer, Morten
    Jensen, Niels Viggo
    Saxe, Charlotte
    Sengeloev, Lisa
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) : 295 - 301
  • [2] Phase I Trial of the Combination of Docetaxel Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer
    Thakur, Manish K.
    Heilbrun, Lance
    Dobson, Kimberlee
    Boerner, Julie
    Stark, Karri
    Li, Jing
    Smith, Daryn
    Heath, Elisabeth
    Fontana, Joseph
    Vaishampayan, Ulka
    CLINICAL GENITOURINARY CANCER, 2018, 16 (03) : E695 - E703
  • [3] A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Zurita, A.
    Shore, N. D.
    Kozloff, M. F.
    Ryan, C. W.
    Beer, T. M.
    Maneval, E. Chow
    Chen, I.
    Logothetis, C. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 287 - 287
  • [4] A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C plus DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).
    Al Harthy, Munjid
    Madan, Ravi Amrit
    Karzai, Fatima
    Petrylak, Daniel Peter
    Kim, Joseph W.
    Arlen, Philip M.
    Theoret, Marc Robert
    Marte, Jenn
    Bilusic, Marijo
    Couvillon, Anna
    Chun, Guinevere
    Owens, Helen
    Hankin, Amy
    Cordes, Lisa M.
    Figg, William Douglas
    Gulley, James L.
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer
    Zhuang, Eric
    Uchio, Edward
    Lilly, Michael
    Zi, Xiaolin
    Fruehauf, John P.
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 143
  • [6] A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC).
    Karzai, Fatima H.
    Madan, Ravi Amrit
    Apolo, Andrea Borghese
    Parnes, Howard L.
    Wright, John Joseph
    Trepel, Jane B.
    Beatson, Melony A.
    Harold, Nancy
    Couvillon, Anna
    Steinberg, Seth M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
    R Petrioli
    A Pascucci
    R Conca
    G Chiriacò
    E Francini
    G Bargagli
    A I Fiaschi
    A Manganelli
    G De Rubertis
    G Barbanti
    R Ponchietti
    G Francini
    British Journal of Cancer, 2011, 104 : 613 - 619
  • [8] Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
    Petrioli, R.
    Pascucci, A.
    Conca, R.
    Chiriaco, G.
    Francini, E.
    Bargagli, G.
    Fiaschi, A. I.
    Manganelli, A.
    De Rubertis, G.
    Barbanti, G.
    Ponchietti, R.
    Francini, G.
    BRITISH JOURNAL OF CANCER, 2011, 104 (04) : 613 - 619
  • [9] A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC)
    Chi, K. N.
    Hotte, S. J.
    Yu, E.
    Eigl, B. J.
    Tannock, I.
    Saad, F.
    North, S.
    Powers, J.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] SYNERGY: A randomized phase III study comparing firstline docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).
    Chi, K. N.
    De Bono, J. S.
    Higano, C. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345